Matthew Schlumbrecht
University of Miami
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Matthew Schlumbrecht.
Journal of Psychosocial Oncology | 2018
Julia Seay; Darryl Mitteldorf; Alena Yankie; William F. Pirl; Erin Kobetz; Matthew Schlumbrecht
ABSTRACT Objective: To better understand survivorship care needs among LGBT cancer survivors. Design: We administered an anonymous online survey. Sample: LGBT cancer survivors living in the United States. Methods: Participants were recruited via the National LGBT Cancer Project. The survey measured sociodemographic characteristics, social support, posttraumatic stress, and survivorship care needs. Results: Approximately 72% of our 114 participants were cisgender male and 87% were white. Almost all participants reported at least some unmet survivorship care needs (73%), with over half of participants reporting unmet psychological and sexuality care needs. Participants who reported their oncologist was not LGBT-competent had greater unmet needs (t(82) = 2.5, p = 0.01) and greater posttraumatic stress (t(91) = 2.1, p = 0.035). Conclusions: LGBT cancer survivors have significant unmet survivorship care needs, and lack of oncologist LGBT-competence is associated with unmet needs. Implications for Psychosocial Providers: Our results suggest the need for LGBT competency training for providers.
Gynecologic oncology reports | 2017
Rachel Berger; Nicholas Waler; Matthew Schlumbrecht; Marilyn Huang
Highlights • Tumor lysis syndrome is rare in solid tumors.• Tumor lysis syndrome is an oncologic emergency.• We present two cases of spontaneous tumor lysis syndrome arising in uterine cancer.
Gynecologic oncology reports | 2017
Reshma Muppala; Talia Donenberg; M. Huang; Matthew Schlumbrecht
Background SMARCA4 is gene whose protein product participates in chromatin remodeling. Somatic mutations in this gene are associated with non-small cell lung cancer and malignant rhabdoid tumors, and both germline and somatic mutations are seen with small cell carcinoma of the ovary, hypercalcemic type. To date, there are no data identifying an association with more common epithelial carcinomas of the ovary. Case The patient is a 57-year-old female without any significant family history of cancer, diagnosed with high-grade serous carcinoma of the ovary. Per guideline, she underwent genetic testing, and was found to have a deleterious germline SMARCA4 mutation. She was treated with standard chemotherapy and an optimal tumor reduction, with a complete response to treatment. Conclusion The etiology of this patients high-grade serous carcinoma is unknown. If the SMARCA4 gene plays a role in serous ovarian carcinoma it is with variable expressivity. Further investigation into the role of SMARCA4 as a susceptibility gene for epithelial ovarian cancer is warranted.
Gynecologic Oncology | 2017
Matthew Schlumbrecht; Jordan Baeker Bispo; Raymond R. Balise; M. Huang; Brian M. Slomovitz; Erin Kobetz
BACKGROUND Minorities have demonstrated an increased risk for type II endometrial cancers, but no data exists about risk among minority subpopulations. Our objective was to evaluate heterogeneity in risk of type II endometrial cancer (EC) histologies across race and Hispanic sub-groups using data from Floridas statewide cancer registry (FCDS). METHODS FCDS contains data on N=26,416 women diagnosed with EC from 2004 to 2013. Our analysis included women ≥18years of age who were classified as non-Hispanic White (NHW), non-Hispanic Black (NHB) or belonged to one of five Hispanic sub-groups, and had a histology code consistent with type I or type II EC. Binary logistic regression analyses were performed to model risk of type II versus type I ECs across racial and ethnic groups relative to NHW. RESULTS Relative to NHW, overall odds of being diagnosed with a type II EC were significantly higher in NHB (OR=2.64, 95%CI: 2.38-2.92), Cubans (OR=1.35, 95%CI: 1.08-1.68) and South and Central Americans (SCA) (OR=1.84, 95%CI: 1.40-2.43). Compared to NHW, odds of serous EC were significantly higher in Cubans (OR=2.15, 95% CI: 1.51-3.05) and NHB (OR=2.51, 95% CI: 2.11-2.97); odds of carcinosarcoma (CS) were significantly higher in NHB (OR=2.97, 95% CI: 2.47-3.57) and Puerto Ricans (OR=2.35, 95%CI: 1.32-4.17); and odds of grade III adenocarcinoma (AG3) were significantly higher in NHB (OR=1.60, 95% CI: 1.42-1.81) and SCA (OR=1.76, 95%CI: 1.29-2.40). CONCLUSION Risk of type II EC varies considerably across Hispanic sub-groups, with Cubans, Puerto Ricans and SCA characterized by elevated odds for specific type II histologies.
BMC Cancer | 2018
Matthew Schlumbrecht; Charlotte C. Sun; M. Huang; Andrea Milbourne; Diane C. Bodurka
Japanese Journal of Cancer and Chemotherapy | 2018
John Siemon; David M. Gershenson; Brian M. Slomovitz; Matthew Schlumbrecht
Gynecologic Oncology | 2018
T. Hunter; Matthew Schlumbrecht; K. Dimentstein; Brian M. Slomovitz; M. Huang
Gynecologic Oncology | 2018
P.N. Kamath; Matthew Schlumbrecht; Sophia George; Brian M. Slomovitz; T. Koru-Sengul; F. Miao; D. Driscoll; S. Oldak; M. Huang
Gynecologic Oncology Research and Practice | 2017
Matthew Schlumbrecht; John Siemon; Guillermo Morales; M. Huang; Brian M. Slomovitz
Gynecologic Oncology | 2017
P.P. Jeudin; M. Huang; J.M. Pearson; Matthew Schlumbrecht; Erin Kobetz; Brian M. Slomovitz